Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.56 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | HNF4A | P41235 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 8/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646566 | 0.99 | PTPN1 (0.57) | PTPN1IDH1MPOHNF4APTPN2 | |
| Potassium SCHEMBL647179 | 0.98 | PTPN1 (0.58) | PTPN1IDH1MPOHNF4APTPN2 | |
| SCHEMBL646573 | 0.91 | PTPN1 (0.55) | PTPN1IDH1MPOPTPN2 | |
| SCHEMBL647970 | 0.90 | PTPN1 (0.56) | PTPN1PTPN2 | |
| SCHEMBL646410 | 0.89 | PTPN1 (0.58) | PTPN1IDH1PTPN2 | |
| SCHEMBL3215930 | 0.89 | PTPN1 (0.56) | PTPN1PTPN2 | |
| SCHEMBL2935327 | 0.89 | PTPN1 (0.56) | PTPN1IDH1MPOHNF4APTPN2 | |
| SCHEMBL647807 | 0.89 | PTPN1 (0.54) | PTPN1MPOHNF4A | |
| SCHEMBL646409 | 0.88 | PTPN1 (0.55) | PTPN1PTPN2 | |
| SCHEMBL650361 | 0.88 | PTPN1 (0.54) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963294-B1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1963294-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067613-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | PTPN1 17/4885IDH1 2081/4885MPO 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.